Fruquintinib in the Cross-line Treatment of Refractory mCRC

Metastatic Colorectal Cancer Clinical Trial

Official title: A Real-world Study of Fruquintinib in the Cross-line Treatment of Refractory mCRC

Status Recruiting

Clinical Trial Summary

This is a real-world study. Patients with metastatic colorectal cancer who have progressed (PD) after third-line treatment with fruquintinib combined with PD-1 inhibitors will receive fruquintinib combined with TAS-102 as fourth-line therapy. The objective of this study was to observe the efficacy and safety of cross-line（from third to fourth line）treatment with fruquinitinib.

Clinical Trial Description

This is a real-world study. Patients with metastatic colorectal cancer confirmed by histopathology had previously received 2-line system therapy with fluorouracil, oxaliplatin, irinotecan, anti-VEGF, anti-EGFR (RAS and BRAF wild type) (treatment with anti-VEGF-TKI is not allowed), and had received fruquinitinib combined with PD-1 inhibitors for third-line treatment. After progression (PD) (confirmed by RECIST 1.1 ), fruquinitinib combined with TAS-102 as fourth-line therapy was received. The primary endpoint was observation the overall survival (OS) of fourth-line treatment of mCRC with fruquinitinib and TAS-102. The study objective is to explore the possibility of cross-line rechallenge of fruquinitinib. ;

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Metastatic Colorectal Cancer

• NCT number: NCT06099314
• Study type: Observational
• Source: Wuhan Union Hospital, China
• Contact: Zhenyu Lin
• Phone: 15827130393
• Email: whxhlzy@hust.edu.cn
• Status: Recruiting
• Start date: October 2023
• Completion date: September 2025